Cellerant Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Cellerant is a clinical-stage biotechnology company developing a portfolio of adult stem cell-derived products that could potentially regulate the hematopoietic (blood forming) system. It currently has two products in clinical development: a highly purified hematopoietic stem cell product that is a curative therapy for sickle cell disease, autoimmune diseases and cancers, and a manufactured cell product for the treatment of neutropenia in patients at risk for infection following stem cell transplant or chemotherapy.
You may also be interested in...
Stem Cells: What's the Business Model?
The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.
Stem Cells: What's the Business Model?
The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.
Cancer Stem Cells: A New Approach to Treating Cancer
Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.